Who are fexofenadine HCl's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Fluticasone furoate and fexofenadine, Diphenhydramine 5%, Azelastine - intranasal application, adrenaline, promethazine, hydrocortisone, fluticasone furoate, fexofenadine, Benadryl demand.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/fexofenadine-hcl.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-14 · How we verify

fexofenadine HCl — Competitive Intelligence Brief

fexofenadine HCl (fexofenadine HCl) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Second-generation H1-receptor antagonist (non-sedating antihistamine). Area: Allergy/Immunology.

marketed Second-generation H1-receptor antagonist (non-sedating antihistamine) H1 histamine receptor Allergy/Immunology Small molecule Live · refreshed every 30 min

Target snapshot

fexofenadine HCl (fexofenadine HCl) — Sanofi. Fexofenadine is a selective H1-receptor antagonist that blocks histamine-mediated allergic responses without crossing the blood-brain barrier.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target
fexofenadine HCl TARGET	fexofenadine HCl	Sanofi	marketed	Second-generation H1-receptor antagonist (non-sedating antihistamine)	H1 histamine receptor
Fluticasone furoate and fexofenadine	Fluticasone furoate and fexofenadine	GlaxoSmithKline	marketed	Intranasal corticosteroid and antihistamine combination	Glucocorticoid receptor (fluticasone furoate); H1 histamine receptor (fexofenadine)
Diphenhydramine 5%	Diphenhydramine 5%	Federal State Budgetary Scientific Institution, Research Institute of Fundamental and Clinical Immunology	marketed	H1 receptor antagonist (first-generation antihistamine)	H1 histamine receptor
Azelastine - intranasal application	Azelastine - intranasal application	Association Asthma, Bulgaria	marketed	Selective H1-receptor antagonist (intranasal antihistamine)	H1 histamine receptor
adrenaline, promethazine, hydrocortisone	adrenaline, promethazine, hydrocortisone	University of Kelaniya	marketed	Combination therapy: sympathomimetic, antihistamine, corticosteroid	Adrenergic receptors (α1, α2, β1, β2); H1 histamine receptor; glucocorticoid receptor
fluticasone furoate, fexofenadine	fluticasone furoate, fexofenadine	GlaxoSmithKline	marketed	Corticosteroid/antihistamine combination	Glucocorticoid receptor (fluticasone furoate); H1 histamine receptor (fexofenadine)
Benadryl demand	Benadryl demand	University of Pennsylvania	marketed	First-generation H1 antihistamine	H1 histamine receptor

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Second-generation H1-receptor antagonist (non-sedating antihistamine) class)

Sanofi · 2 drugs in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). fexofenadine HCl — Competitive Intelligence Brief. https://druglandscape.com/ci/fexofenadine-hcl. Accessed 2026-05-14.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab